Loading…

Arsenic trioxide prevents rat pulmonary fibrosis via miR-98 overexpression

This study aimed to investigate the pathogenesis mechanisms of bleomycin (BLM)-induced pulmonary fibrosis (PF) in Sprague–Dawley rats and explore the anti-fibrotic role of arsenic trioxide (As2O3) in preventing PF. Intratracheal instillation of BLM was performed to establish PF rat models. The treat...

Full description

Saved in:
Bibliographic Details
Published in:Life sciences (1973) 2014-09, Vol.114 (1), p.20-28
Main Authors: Gao, Shu-Yan, Zhou, Xue, Li, You-Jie, Liu, Wei-Li, Wang, Ping-Yu, Pang, Min, Xie, Shu-Yang, Lv, Chang-Jun
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c353t-dc2ccd0fc44b6c74a2d5047578f2b1eea9c2545574c4c7330106b28350f57d053
cites cdi_FETCH-LOGICAL-c353t-dc2ccd0fc44b6c74a2d5047578f2b1eea9c2545574c4c7330106b28350f57d053
container_end_page 28
container_issue 1
container_start_page 20
container_title Life sciences (1973)
container_volume 114
creator Gao, Shu-Yan
Zhou, Xue
Li, You-Jie
Liu, Wei-Li
Wang, Ping-Yu
Pang, Min
Xie, Shu-Yang
Lv, Chang-Jun
description This study aimed to investigate the pathogenesis mechanisms of bleomycin (BLM)-induced pulmonary fibrosis (PF) in Sprague–Dawley rats and explore the anti-fibrotic role of arsenic trioxide (As2O3) in preventing PF. Intratracheal instillation of BLM was performed to establish PF rat models. The treatment group was treated with As2O3 (0.4mg/kg/day). Morphological changes were observed by hematoxylin–eosin and Masson staining. Related proteins were determined by immunohistochemistry, immunofluorescence, and Western blot. MicroRNA detection was performed by quantitative real-time polymerase chain reaction. As a novel miRNA in PF, miR-98 decreased in the fibrotic lung tissues. Based on microRNA analysis software, we found that Stat3-3′-UTR is targeted by miR-98. Then, we found that Stat3 was activated with PF development and the expression of Stat3 and p-Stat3 was significantly increased in BLM-induced PF at day 28 compared with saline-treated rats. Our results showed that both Stat3 and p-Stat3 were significantly decreased in miR-98-treated A549 cells compared with that in mu-98-treated cultures or untreated controls. The fibrotic marker α-SMA was upregulated, whereas E-cadherin was inhibited in fibrotic lung tissues. The ratio of apoptotic factors Bax/Bcl-2 increased with the development of fibrosis. Furthermore, As2O3 treatment prevented lung interstitial thickening and inhibited the collagen type I and hydroxyproline, thereby preventing the development of PF. As2O3 also significantly down-regulated α-SMA but increased E-cadherin and miR-98 levels. The study revealed that arsenic trioxide prevented rat PF by up-regulation of miR-98 and inhibition of its downstream Stat3 signals. [Display omitted]
doi_str_mv 10.1016/j.lfs.2014.07.037
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1561979952</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0024320514006687</els_id><sourcerecordid>1561979952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-dc2ccd0fc44b6c74a2d5047578f2b1eea9c2545574c4c7330106b28350f57d053</originalsourceid><addsrcrecordid>eNp9kEtLw0AUhQdRbK3-ADeSpZvEO69MgqtSfFIQRNdDMrmBKXnUmSTUf--UVpeu7uacc8_5CLmmkFCg6d0maWqfMKAiAZUAVydkTjOVx5ByekrmAEzEnIGckQvvNwAgpeLnZMYkZVxyOSevS-exsyYanO13tsJo63DCbvCRK4ZoOzZt3xXuO6pt6XpvfTTZImrte5xnUT-hw10weG_77pKc1UXj8ep4F-Tz8eFj9Ryv355eVst1bMLLIa4MM6aC2ghRpkaJglUShJIqq1lJEYvcMClCUWGEUZwDhbRkGZdQS1WB5Atye8jduv5rRD_o1nqDTVN02I9eU5nSXOW5ZEFKD1ITunuHtd4624Y5moLeI9QbHRDqPUINSgeEwXNzjB_LFqs_xy-zILg_CDCMnCw67Y3FzmBlHZpBV739J_4HgceBTQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1561979952</pqid></control><display><type>article</type><title>Arsenic trioxide prevents rat pulmonary fibrosis via miR-98 overexpression</title><source>ScienceDirect Journals</source><creator>Gao, Shu-Yan ; Zhou, Xue ; Li, You-Jie ; Liu, Wei-Li ; Wang, Ping-Yu ; Pang, Min ; Xie, Shu-Yang ; Lv, Chang-Jun</creator><creatorcontrib>Gao, Shu-Yan ; Zhou, Xue ; Li, You-Jie ; Liu, Wei-Li ; Wang, Ping-Yu ; Pang, Min ; Xie, Shu-Yang ; Lv, Chang-Jun</creatorcontrib><description>This study aimed to investigate the pathogenesis mechanisms of bleomycin (BLM)-induced pulmonary fibrosis (PF) in Sprague–Dawley rats and explore the anti-fibrotic role of arsenic trioxide (As2O3) in preventing PF. Intratracheal instillation of BLM was performed to establish PF rat models. The treatment group was treated with As2O3 (0.4mg/kg/day). Morphological changes were observed by hematoxylin–eosin and Masson staining. Related proteins were determined by immunohistochemistry, immunofluorescence, and Western blot. MicroRNA detection was performed by quantitative real-time polymerase chain reaction. As a novel miRNA in PF, miR-98 decreased in the fibrotic lung tissues. Based on microRNA analysis software, we found that Stat3-3′-UTR is targeted by miR-98. Then, we found that Stat3 was activated with PF development and the expression of Stat3 and p-Stat3 was significantly increased in BLM-induced PF at day 28 compared with saline-treated rats. Our results showed that both Stat3 and p-Stat3 were significantly decreased in miR-98-treated A549 cells compared with that in mu-98-treated cultures or untreated controls. The fibrotic marker α-SMA was upregulated, whereas E-cadherin was inhibited in fibrotic lung tissues. The ratio of apoptotic factors Bax/Bcl-2 increased with the development of fibrosis. Furthermore, As2O3 treatment prevented lung interstitial thickening and inhibited the collagen type I and hydroxyproline, thereby preventing the development of PF. As2O3 also significantly down-regulated α-SMA but increased E-cadherin and miR-98 levels. The study revealed that arsenic trioxide prevented rat PF by up-regulation of miR-98 and inhibition of its downstream Stat3 signals. [Display omitted]</description><identifier>ISSN: 0024-3205</identifier><identifier>EISSN: 1879-0631</identifier><identifier>DOI: 10.1016/j.lfs.2014.07.037</identifier><identifier>PMID: 25123535</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Actins - genetics ; Animals ; Arsenicals - pharmacology ; As2O3 ; Bleomycin - toxicity ; Cadherins - metabolism ; Collagen Type I - metabolism ; Down-Regulation - drug effects ; Gene expression ; Hydroxyproline - metabolism ; Male ; MicroRNAs - genetics ; miR-98 ; Oxides - pharmacology ; Pulmonary fibrosis ; Pulmonary Fibrosis - genetics ; Pulmonary Fibrosis - pathology ; Pulmonary Fibrosis - prevention &amp; control ; Rats ; Rats, Sprague-Dawley ; Real-Time Polymerase Chain Reaction ; Signal Transduction - drug effects ; Stat3 signals ; STAT3 Transcription Factor - metabolism ; Up-Regulation - drug effects</subject><ispartof>Life sciences (1973), 2014-09, Vol.114 (1), p.20-28</ispartof><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-dc2ccd0fc44b6c74a2d5047578f2b1eea9c2545574c4c7330106b28350f57d053</citedby><cites>FETCH-LOGICAL-c353t-dc2ccd0fc44b6c74a2d5047578f2b1eea9c2545574c4c7330106b28350f57d053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25123535$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gao, Shu-Yan</creatorcontrib><creatorcontrib>Zhou, Xue</creatorcontrib><creatorcontrib>Li, You-Jie</creatorcontrib><creatorcontrib>Liu, Wei-Li</creatorcontrib><creatorcontrib>Wang, Ping-Yu</creatorcontrib><creatorcontrib>Pang, Min</creatorcontrib><creatorcontrib>Xie, Shu-Yang</creatorcontrib><creatorcontrib>Lv, Chang-Jun</creatorcontrib><title>Arsenic trioxide prevents rat pulmonary fibrosis via miR-98 overexpression</title><title>Life sciences (1973)</title><addtitle>Life Sci</addtitle><description>This study aimed to investigate the pathogenesis mechanisms of bleomycin (BLM)-induced pulmonary fibrosis (PF) in Sprague–Dawley rats and explore the anti-fibrotic role of arsenic trioxide (As2O3) in preventing PF. Intratracheal instillation of BLM was performed to establish PF rat models. The treatment group was treated with As2O3 (0.4mg/kg/day). Morphological changes were observed by hematoxylin–eosin and Masson staining. Related proteins were determined by immunohistochemistry, immunofluorescence, and Western blot. MicroRNA detection was performed by quantitative real-time polymerase chain reaction. As a novel miRNA in PF, miR-98 decreased in the fibrotic lung tissues. Based on microRNA analysis software, we found that Stat3-3′-UTR is targeted by miR-98. Then, we found that Stat3 was activated with PF development and the expression of Stat3 and p-Stat3 was significantly increased in BLM-induced PF at day 28 compared with saline-treated rats. Our results showed that both Stat3 and p-Stat3 were significantly decreased in miR-98-treated A549 cells compared with that in mu-98-treated cultures or untreated controls. The fibrotic marker α-SMA was upregulated, whereas E-cadherin was inhibited in fibrotic lung tissues. The ratio of apoptotic factors Bax/Bcl-2 increased with the development of fibrosis. Furthermore, As2O3 treatment prevented lung interstitial thickening and inhibited the collagen type I and hydroxyproline, thereby preventing the development of PF. As2O3 also significantly down-regulated α-SMA but increased E-cadherin and miR-98 levels. The study revealed that arsenic trioxide prevented rat PF by up-regulation of miR-98 and inhibition of its downstream Stat3 signals. [Display omitted]</description><subject>Actins - genetics</subject><subject>Animals</subject><subject>Arsenicals - pharmacology</subject><subject>As2O3</subject><subject>Bleomycin - toxicity</subject><subject>Cadherins - metabolism</subject><subject>Collagen Type I - metabolism</subject><subject>Down-Regulation - drug effects</subject><subject>Gene expression</subject><subject>Hydroxyproline - metabolism</subject><subject>Male</subject><subject>MicroRNAs - genetics</subject><subject>miR-98</subject><subject>Oxides - pharmacology</subject><subject>Pulmonary fibrosis</subject><subject>Pulmonary Fibrosis - genetics</subject><subject>Pulmonary Fibrosis - pathology</subject><subject>Pulmonary Fibrosis - prevention &amp; control</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Real-Time Polymerase Chain Reaction</subject><subject>Signal Transduction - drug effects</subject><subject>Stat3 signals</subject><subject>STAT3 Transcription Factor - metabolism</subject><subject>Up-Regulation - drug effects</subject><issn>0024-3205</issn><issn>1879-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLw0AUhQdRbK3-ADeSpZvEO69MgqtSfFIQRNdDMrmBKXnUmSTUf--UVpeu7uacc8_5CLmmkFCg6d0maWqfMKAiAZUAVydkTjOVx5ByekrmAEzEnIGckQvvNwAgpeLnZMYkZVxyOSevS-exsyYanO13tsJo63DCbvCRK4ZoOzZt3xXuO6pt6XpvfTTZImrte5xnUT-hw10weG_77pKc1UXj8ep4F-Tz8eFj9Ryv355eVst1bMLLIa4MM6aC2ghRpkaJglUShJIqq1lJEYvcMClCUWGEUZwDhbRkGZdQS1WB5Atye8jduv5rRD_o1nqDTVN02I9eU5nSXOW5ZEFKD1ITunuHtd4624Y5moLeI9QbHRDqPUINSgeEwXNzjB_LFqs_xy-zILg_CDCMnCw67Y3FzmBlHZpBV739J_4HgceBTQ</recordid><startdate>20140926</startdate><enddate>20140926</enddate><creator>Gao, Shu-Yan</creator><creator>Zhou, Xue</creator><creator>Li, You-Jie</creator><creator>Liu, Wei-Li</creator><creator>Wang, Ping-Yu</creator><creator>Pang, Min</creator><creator>Xie, Shu-Yang</creator><creator>Lv, Chang-Jun</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140926</creationdate><title>Arsenic trioxide prevents rat pulmonary fibrosis via miR-98 overexpression</title><author>Gao, Shu-Yan ; Zhou, Xue ; Li, You-Jie ; Liu, Wei-Li ; Wang, Ping-Yu ; Pang, Min ; Xie, Shu-Yang ; Lv, Chang-Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-dc2ccd0fc44b6c74a2d5047578f2b1eea9c2545574c4c7330106b28350f57d053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Actins - genetics</topic><topic>Animals</topic><topic>Arsenicals - pharmacology</topic><topic>As2O3</topic><topic>Bleomycin - toxicity</topic><topic>Cadherins - metabolism</topic><topic>Collagen Type I - metabolism</topic><topic>Down-Regulation - drug effects</topic><topic>Gene expression</topic><topic>Hydroxyproline - metabolism</topic><topic>Male</topic><topic>MicroRNAs - genetics</topic><topic>miR-98</topic><topic>Oxides - pharmacology</topic><topic>Pulmonary fibrosis</topic><topic>Pulmonary Fibrosis - genetics</topic><topic>Pulmonary Fibrosis - pathology</topic><topic>Pulmonary Fibrosis - prevention &amp; control</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Real-Time Polymerase Chain Reaction</topic><topic>Signal Transduction - drug effects</topic><topic>Stat3 signals</topic><topic>STAT3 Transcription Factor - metabolism</topic><topic>Up-Regulation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gao, Shu-Yan</creatorcontrib><creatorcontrib>Zhou, Xue</creatorcontrib><creatorcontrib>Li, You-Jie</creatorcontrib><creatorcontrib>Liu, Wei-Li</creatorcontrib><creatorcontrib>Wang, Ping-Yu</creatorcontrib><creatorcontrib>Pang, Min</creatorcontrib><creatorcontrib>Xie, Shu-Yang</creatorcontrib><creatorcontrib>Lv, Chang-Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Life sciences (1973)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gao, Shu-Yan</au><au>Zhou, Xue</au><au>Li, You-Jie</au><au>Liu, Wei-Li</au><au>Wang, Ping-Yu</au><au>Pang, Min</au><au>Xie, Shu-Yang</au><au>Lv, Chang-Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Arsenic trioxide prevents rat pulmonary fibrosis via miR-98 overexpression</atitle><jtitle>Life sciences (1973)</jtitle><addtitle>Life Sci</addtitle><date>2014-09-26</date><risdate>2014</risdate><volume>114</volume><issue>1</issue><spage>20</spage><epage>28</epage><pages>20-28</pages><issn>0024-3205</issn><eissn>1879-0631</eissn><abstract>This study aimed to investigate the pathogenesis mechanisms of bleomycin (BLM)-induced pulmonary fibrosis (PF) in Sprague–Dawley rats and explore the anti-fibrotic role of arsenic trioxide (As2O3) in preventing PF. Intratracheal instillation of BLM was performed to establish PF rat models. The treatment group was treated with As2O3 (0.4mg/kg/day). Morphological changes were observed by hematoxylin–eosin and Masson staining. Related proteins were determined by immunohistochemistry, immunofluorescence, and Western blot. MicroRNA detection was performed by quantitative real-time polymerase chain reaction. As a novel miRNA in PF, miR-98 decreased in the fibrotic lung tissues. Based on microRNA analysis software, we found that Stat3-3′-UTR is targeted by miR-98. Then, we found that Stat3 was activated with PF development and the expression of Stat3 and p-Stat3 was significantly increased in BLM-induced PF at day 28 compared with saline-treated rats. Our results showed that both Stat3 and p-Stat3 were significantly decreased in miR-98-treated A549 cells compared with that in mu-98-treated cultures or untreated controls. The fibrotic marker α-SMA was upregulated, whereas E-cadherin was inhibited in fibrotic lung tissues. The ratio of apoptotic factors Bax/Bcl-2 increased with the development of fibrosis. Furthermore, As2O3 treatment prevented lung interstitial thickening and inhibited the collagen type I and hydroxyproline, thereby preventing the development of PF. As2O3 also significantly down-regulated α-SMA but increased E-cadherin and miR-98 levels. The study revealed that arsenic trioxide prevented rat PF by up-regulation of miR-98 and inhibition of its downstream Stat3 signals. [Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>25123535</pmid><doi>10.1016/j.lfs.2014.07.037</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0024-3205
ispartof Life sciences (1973), 2014-09, Vol.114 (1), p.20-28
issn 0024-3205
1879-0631
language eng
recordid cdi_proquest_miscellaneous_1561979952
source ScienceDirect Journals
subjects Actins - genetics
Animals
Arsenicals - pharmacology
As2O3
Bleomycin - toxicity
Cadherins - metabolism
Collagen Type I - metabolism
Down-Regulation - drug effects
Gene expression
Hydroxyproline - metabolism
Male
MicroRNAs - genetics
miR-98
Oxides - pharmacology
Pulmonary fibrosis
Pulmonary Fibrosis - genetics
Pulmonary Fibrosis - pathology
Pulmonary Fibrosis - prevention & control
Rats
Rats, Sprague-Dawley
Real-Time Polymerase Chain Reaction
Signal Transduction - drug effects
Stat3 signals
STAT3 Transcription Factor - metabolism
Up-Regulation - drug effects
title Arsenic trioxide prevents rat pulmonary fibrosis via miR-98 overexpression
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T04%3A17%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Arsenic%20trioxide%20prevents%20rat%20pulmonary%20fibrosis%20via%20miR-98%20overexpression&rft.jtitle=Life%20sciences%20(1973)&rft.au=Gao,%20Shu-Yan&rft.date=2014-09-26&rft.volume=114&rft.issue=1&rft.spage=20&rft.epage=28&rft.pages=20-28&rft.issn=0024-3205&rft.eissn=1879-0631&rft_id=info:doi/10.1016/j.lfs.2014.07.037&rft_dat=%3Cproquest_cross%3E1561979952%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c353t-dc2ccd0fc44b6c74a2d5047578f2b1eea9c2545574c4c7330106b28350f57d053%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1561979952&rft_id=info:pmid/25123535&rfr_iscdi=true